Millennium Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Millennium Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.4M	Buy	636,187 +60,095	+10%	+$1.09M	﹤0.01%	2071
2026 Q1	$10.7M	Sell	576,092 -226,630	-28%	-$3.75M	﹤0.01%	2110
2025 Q4	$10.6M	Buy	802,722 +713,550	+800%	+$8.42M	﹤0.01%	2207
2025 Q3	$639K	Buy	+89,172	New	+$4.65M	﹤0.01%	4926
2025 Q2	–	Sell	-344,320	Closed	-$13.5M	–	6169
2025 Q1	$13.5M	Buy	+344,320	New	+$14.8M	0.01%	1894
2024 Q4	–	Sell	-51,267	Closed	-$2.62M	–	6253
2024 Q3	$2.58M	Sell	51,267 -165,697	-76%	-$7.76M	﹤0.01%	3466
2024 Q2	$9.54M	Buy	216,964 +195,989	+934%	+$8.3M	﹤0.01%	2114
2024 Q1	$1.05M	Sell	20,975 -53,133	-72%	-$2.88M	﹤0.01%	4251
2023 Q4	$4.48M	Buy	74,108 +43,578	+143%	+$2.25M	﹤0.01%	2885
2023 Q3	$1.74M	Sell	30,530 -161,874	-84%	-$8.94M	﹤0.01%	3690
2023 Q2	$9.81M	Buy	192,404 +157,333	+449%	+$4.23M	﹤0.01%	2047
2023 Q1	$750K	Buy	+35,071	New	+$590K	﹤0.01%	4329
2022 Q3	–	Sell	-28,090	Closed	-$147K	–	7335
2022 Q2	$147K	Sell	28,090 -120,135	-81%	-$755K	﹤0.01%	5777
2022 Q1	$1.65M	Buy	148,225 +92,490	+166%	+$920K	﹤0.01%	4060
2021 Q4	$551K	Hold	55,735	–	–	﹤0.01%	4958
2021 Q3	$555K	Hold	55,735	–	–	﹤0.01%	5254
2021 Q2	$577K	Buy	55,735 +35,735	+179%	+$363K	﹤0.01%	5170
2021 Q1	$204K	Hold	20,000	–	–	﹤0.01%	5486
2020 Q4	$227K	Buy	+20,000	New	+$212K	﹤0.01%	4737

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management's MLTX Position: Q2 2026 in Review

Millennium Management increased its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q2 2026, buying an estimated $1.09M and bringing the position to 636,187 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Millennium Management first reported a position in MLTX in Q4 2020 and has held it in 19 quarters since. The position peaked at $13.5M in Q1 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Millennium Management held 636,187 shares of MoonLake Immunotherapeutics worth $12.4M as of Q2 2026.
Millennium Management bought 60,095 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.09M.
MoonLake Immunotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #2071 holding.
Millennium Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 19 quarters since.
Millennium Management's MoonLake Immunotherapeutics position peaked at $13.5M in Q1 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.